Regeneron Reports Third Quarter 2019 Financial and Operating Results
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: PR Newswire
TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ --Third quarter 2019 revenues increased 23% to $2.05 billion versus third quarter 2018 Third quarter EYLEA® U.S. net sales increased 16% to $1.19 billion versus third quarter 2018 Dupixent® global net sales(5), which increased 141% to $633 million versus third quarter 2018, drove higher profitability from antibody collaboration with Sanofi Third quarter 2019 GAAP diluted EPS was $5.86 and third quarter non-GAAP diluted EPS(1) was $6.67 Company announces $1.0 billion share repurchase programRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2019 and provided a business update."Regeneron delivered positive financial and operational results this quarter, marked by significant EYLEA and Dupixent sales growth and progress across our pipeline," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "We are broadening our efforts in retinal and type 2 inflam
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.MarketBeat
- Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease [Yahoo! Finance]Yahoo! Finance
- Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASHGlobeNewswire
- Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales [Yahoo! Finance]Yahoo! Finance
- Regeneron Announces Investor Conference PresentationsGlobeNewswire
REGN
Earnings
- 10/31/24 - Beat
REGN
Sec Filings
- 11/12/24 - Form 4
- 11/5/24 - Form 4
- 11/1/24 - Form 144
- REGN's page on the SEC website